Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program

BACKGROUND: Canagliflozin is approved for glucose lowering in type 2 diabetes and confers cardiovascular and renal benefits. We sought to assess whether it had benefits in people with chronic kidney disease, including those with an estimated glomerular filtration rate (eGFR) between 30 and 45 mL/min...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Circulation
Main Authors: Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Desai, Mehul, Li, Qiang, Deng, Hsiaowei, Rosenthal, Norm, Jardine, Meg J., Bakris, George, Perkovic, Vlado
Format: Artigo
Sprog:Inglês
Udgivet: Lippincott Williams & Wilkins 2018
Fag:
Original Research Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6181277/
https://ncbi.nlm.nih.gov/pubmed/29941478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker